Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study
Low-dose rapamycin effectively reduced PEM and other key symptoms in patients with ME/CFS, as measured by BAS, SSS, MFI, and SF-36. Future studies should encompass dose optimization and develop a diagnostic tool to identify responders with mTOR-mediated autophagy disruption.
Authors
- B Ruan (ORCID: https://orcid.org/0009-0002-5554-8631)
- Brayden Yellman
- David L. Kaufman (ORCID: https://orcid.org/0000-0002-0239-2920)
- Jennifer Bell (ORCID: https://orcid.org/0000-0003-3617-6852)
- C. Gunnar Gottschalk (ORCID: https://orcid.org/0000-0003-4229-2542)
- Jon Berner (ORCID: https://orcid.org/0000-0003-3117-6482)
- Bela Chheda
- Sarojini Bulbule (ORCID: https://orcid.org/0000-0003-2787-3058)
- Stephanie L. Grach (ORCID: https://orcid.org/0000-0002-8337-6219)
- Lucinda Bateman (ORCID: https://orcid.org/0000-0002-9546-9922)
- Avik Roy (ORCID: https://orcid.org/0000-0003-0523-8504)
- Amy Reyes
- Daniel L. Peterson
- Brooke Gile
Institutions
- Palo Alto Research Center (US)
- Cornell University (US)
- Sierra Nevada College (US)
- Methodist Hospital (US)
- Cancer Targeted Technology (United States) (US)
- Seattle Photonics Associates (United States) (US)
- Mayo Clinic in Arizona (US)
- Bateman Horne Center (US)
- Centerforce (US)
- University of Wisconsin–Milwaukee (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1186/s12967-025-07213-8
- Citations
- 3
- Primary Topic
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences